Aradigm Corp. (ARDM) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aradigm Announces Fourth Quarter 2015 and Full Year Financial Results
March 15, 2016 7:00 AM EDTHAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the Company) today announced financial results for the fourth quarter and full year ended December 31, 2015.
Fourth Quarter 2015 Results
Since the Company has utilized the full amount of the $65 million of Grifols-funded budget provided under the inhaled ciprofloxacin collaboration arrangement which is recognized as revenue for reimbursement of its investigational drug Pulmaquin® inhaled ciprofloxacin project-related costs the Company recorded $35,000 in revenue in the fourth quarter of 2015 compared with $8.1 million in revenue in the fourth quarter of 2014. The Company will not be... More
